Avalo Therapeutics (AVTX) Asset Writedowns and Impairment (2018)
Avalo Therapeutics (AVTX) posted Asset Writedowns and Impairment of $38438.0 for Q4 2018, down 75.93% on a QoQ basis from $159687.0 in Q3 2018.
Avalo Therapeutics (AVTX) Asset Writedowns and Impairment (2018) Analysis & Trends
Avalo Therapeutics' Asset Writedowns and Impairment history runs 1 years deep, the most recent figure standing at $38438.0 for Q4 2018.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $38438.0 in Q4 2018, while the trailing twelve-month figure through Sep 2020 was $38438.0 (down 97.98% YoY) and the FY2019 annual result came in at $1.4 million, down 23.73% from the prior year.
- Asset Writedowns and Impairment was $38438.0 for Q4 2018 at Avalo Therapeutics, down from $159687.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $1.7 million in Q2 2018 and bottomed at $38438.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - |
| 2 | Nanobiotix | 1,933.35 Bn | 1,933.29 Bn | - |
| 3 | Akari Therapeutics | 1,063.56 Bn | 1,063.56 Bn | - |
| 4 | BeOne Medicines | 468.54 Bn | 463.75 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.20 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.57 Bn | 63.57 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.75 Bn | 34.74 Bn | 959.66 Mn |
| 10 | Avalo Therapeutics | 386.46 Mn | 329.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 38,438.00 |
| Dec 31, 2018 | 38,438.00 |
| Sep 30, 2018 | 159,687.00 |
| Sep 30, 2018 | 159,687.00 |
| Jun 30, 2018 | 1.70 Mn |
| Jun 30, 2018 | 1.70 Mn |